Genitourinary Cancer News

Most cancer drug approvals between 2016 and 2021 applied to second-, third- or later-line treatment settings and did not displace current standard-of-care therapies, according to a study published in JAMA Network Open.

In this video, Mark W. Ball, MD, discusses updates from the KEYNOTE-564 study on the use of adjuvant pembrolizumab in certain patients with renal cell carcinoma presented at the 2022 ASCO Genitourinary Cancers Symposium.

In a research collaboration with Mayo Clinic, nanomedical company NaNotics LLC plans to develop and assess a novel subtractive nanoparticle for use in cancer treatment.

The FDA granted fast track designation to ALLO-316, an investigational chimeric antigen receptor T-cell therapy, for the treatment of adults with advanced or metastatic clear cell renal cell carcinoma.

Black Medicare beneficiaries who underwent elective cancer surgery had higher rates of mortality than their white counterparts, irrespective of neighborhood deprivation or dual eligibility status, according to study results.

Healio spoke with Tanya Dorff, MD, section chief of the genitourinary disease program at City of Hope, about a study evaluating the use of a chimeric antigen receptor T-cell therapy in a subgroup of patients with prostate cancer.

Among individuals with certain cancers, treatment with radiotherapy was associated with poorer long-term CV-specific survival compared with those who did not undergo radiotherapy, researchers reported.

Daily electronic patient-reported outcome assessments may provide valuable insight into symptom management among patients with cancer undergoing antineoplastic treatment, according to a study published in JAMA Network Open.

Tanya Dorff, MD, section chief of the genitourinary disease program at City of Hope, spoke with Healio about results from the ARASENS trial presented at the 2022 ASCO Genitourinary Cancers Symposium.

Among 126 children diagnosed with a Wilms’ tumor, 42 showed hereditary factors, according to data published in the Journal of Clinical Oncology.